Journal of Gastroenterology

, Volume 45, Issue 7, pp 750–757 | Cite as

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH

  • Yuki Kimura
  • Hideyuki Hyogo
  • Sho-ichi Yamagishi
  • Masayoshi Takeuchi
  • Tomokazu Ishitobi
  • Yoshitaka Nabeshima
  • Koji Arihiro
  • Kazuaki Chayama
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

Advanced glycation endproducts (AGEs), final reaction products of protein with sugars, are known to contribute to various disorders, including diabetes, aspects of aging, and neurodegenerative diseases. Recently, we reported elevated levels of serum AGEs in patients with nonalcoholic steatohepatitis (NASH); further, we found that AGEs induced the generation of reactive oxygen species followed by the proliferation and activation of hepatic stellate cells, a major contributor to liver fibrosis. In this study, to explore the clinical usefulness of AGEs as a biomarker for the attenuation of NASH, we investigated whether the treatment of NASH with dyslipidemia could decrease serum levels of AGEs.

Methods

This study included 43 patients with biopsy-proven NASH with dyslipidemia. Serum glyceraldehyde-derived AGE measurements and clinical laboratory tests were performed periodically during an open-label study of atorvastatin (10 mg daily) for 12 months. Standard weight-loss counseling was continued during the treatment period. Oral glucose tolerance tests and liver density assessment by computerized tomography were performed before and after treatment. Follow-up liver biopsy was performed in 22 patients.

Results

All 43 patients had dyslipidemia. The body mass indexes and serum glucose levels did not change during the treatment. After the treatment, NASH-related metabolic parameters were significantly improved. Serum glyceraldehyde-derived AGE levels were significantly decreased (10.4 ± 3.8 and 2.5 ± 1.1 IU/mL before and after treatment, respectively). The steatosis grade and nonalcoholic fatty liver disease (NAFLD) activity score were significantly improved.

Conclusions

The present data demonstrated that atorvastatin decreased the serum levels of AGEs in NASH patients with dyslipidemia and suggest the usefulness of AGEs as a biomarker for the attenuation of NASH.

Keywords

NASH with dyslipidemia Atorvastatin Advanced glycation endproducts Biomarker 

Abbreviations

NASH

Nonalcoholic steatohepatitis

NAFLD

Nonalcoholic fatty liver disease

IR

Insulin resistance

glycer-AGE

Glyceraldehyde-derived advanced glycation endproducts

AGEs

Advanced glycation endproducts

RAGE

Receptor for AGEs

ROS

Reactive oxygen species

TBARS

Thiobarbituric acid reactive substances

OGTT

Oral glucose tolerance test

IGT

Impaired glucose tolerance

DM

Diabetes mellitus

HOMA-IR

Homeostasis model-IR: NAS

NAFLD

Activity score

IGT

Impaired glucose tolerance

BMI

Body mass index

TNF-α

Tumor necrosis factor-α

FFA

Free fatty acid

P-III-P

Procollagen type III propeptide

HMG-CoA

3-Hydroxy-3-methylglutaryl-coenzyme A

References

  1. 1.
    Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004;53:750–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefPubMedGoogle Scholar
  4. 4.
    James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet. 1999;353:1634–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Hui JM, Farrell GC. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them. J Gastroenterol Hepatol. 2003;18:1115–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Hyogo H, Iwamoto K, Arihiro K, Takeuchi M, Sato T, Ochi H, et al. Elevated levels of serum advanced glycation end products in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2007;22:1114–9.CrossRefGoogle Scholar
  10. 10.
    Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res. 2003;23:129–34.PubMedGoogle Scholar
  11. 11.
    Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia. 2003;46:284–7.PubMedGoogle Scholar
  12. 12.
    Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun. 2002;296:877–82.CrossRefPubMedGoogle Scholar
  13. 13.
    Miele C, Riboulet A, Maitan MA, Oriente F, Romano C, Formisano P, et al. Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism. J Biol Chem. 2003;278:47376–87.CrossRefPubMedGoogle Scholar
  14. 14.
    Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11:2279–99.CrossRefPubMedGoogle Scholar
  15. 15.
    Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol. 2008;43:298–304.CrossRefPubMedGoogle Scholar
  16. 16.
    Hyogo H, Yamagishi S. Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des. 2008;14:969–72.CrossRefPubMedGoogle Scholar
  17. 17.
    Whalan DJ. The ethics and morality of clinical trials in man. Med J Aust. 1975;1:491–4.Google Scholar
  18. 18.
    Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008;57:1711–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003;26(Suppl 1):S5–20.Google Scholar
  20. 20.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med. 2000;6:114–25.PubMedGoogle Scholar
  22. 22.
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefPubMedGoogle Scholar
  23. 23.
    Japanese Society for the Study of Obesity. New criteria of obesity (in Japanese). J Jpn Soc Study Obes. 2000;6:18–28.Google Scholar
  24. 24.
    Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003;17:713–8.PubMedGoogle Scholar
  25. 25.
    Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, et al. Efficacy of omega-3 acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol. 2004;23:127–8.Google Scholar
  26. 26.
    Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther. 2006;23:1643–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006;22:873–83.CrossRefPubMedGoogle Scholar
  28. 28.
    Funatsu T, Goto M, Kakuta H, Suzuki M, Ida M, Nishijima S, et al. Reduction in hepatic nonesterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats. Biochim Biophys Acta. 2002;1580:161–70.PubMedGoogle Scholar
  29. 29.
    Isusi E, Aspichueta P, Liza M, Hernández ML, Díaz C, Hernández G, et al. Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes. Atherosclerosis. 2000;153:283–94.CrossRefPubMedGoogle Scholar
  30. 30.
    Kainuma M, Fujimoto M, Sekiya N, Tsuneyama K, Cheng C, Takano Y, et al. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non–insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol. 2006;41:971–80.CrossRefPubMedGoogle Scholar
  31. 31.
    Nakamura K, Yamagishi SI, Matsui T, Adachi H, Takeuchi M, Imaizumi T, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med. 2007;7:188–90.CrossRefPubMedGoogle Scholar
  32. 32.
    Yamagishi SI, Matsui T, Adachi H, Takeuchi M. Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. Pharmacol Res. 2009; doi:10.1016/j.phrs.2009.07.003.
  33. 33.
    Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev. 2008;24:109–14.CrossRefPubMedGoogle Scholar
  34. 34.
    Yamagishi S, Amano S, Inagaki Y, Okamoto T, Koga K, Sasaki N, et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun. 2002;290:973–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001;108:261–8.PubMedGoogle Scholar
  36. 36.
    Yamamoto Y, Yamagishi S, Yonekura H, Doi T, Tsuji H, Kato I, et al. Roles of the AGE–RAGE system in vascular injury in diabetes. Ann N Y Acad Sci. 2000;902:163–70. discussion 170–2.PubMedCrossRefGoogle Scholar
  37. 37.
    Ishitobi T, Hyogo H, Yamagishi S, Kimura Y, Nabeshimai Y, Tazuma S, et al. Effects of Advanced Glycation End-products and High Glucose on Hepatocytes. Jpn Pharmacol Ther. 2008;36:189–91.Google Scholar
  38. 38.
    Jinnouchi Y, Yamagishi S, Takeuchi M, Ishida S, Jinnouchi Y, Jinnouchi J, et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med. 2006;6:191–3.CrossRefPubMedGoogle Scholar
  39. 39.
    Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–90.CrossRefPubMedGoogle Scholar
  40. 40.
    Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 1998;138:271–80.CrossRefPubMedGoogle Scholar
  41. 41.
    Yoshiike N, Lwin H. Epidemiological aspects of obesity and NASH/NAFLD in Japan. Hepatol Res. 2005;33:77–82.CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Yuki Kimura
    • 1
  • Hideyuki Hyogo
    • 1
  • Sho-ichi Yamagishi
    • 2
  • Masayoshi Takeuchi
    • 3
  • Tomokazu Ishitobi
    • 1
  • Yoshitaka Nabeshima
    • 1
  • Koji Arihiro
    • 4
  • Kazuaki Chayama
    • 1
  1. 1.Department of Medicine and Molecular Science, Graduate School of Biomedical SciencesHiroshima UniversityHiroshimaJapan
  2. 2.Department of Pathophysiology and Therapeutics of Diabetic Vascular ComplicationsKurume University School of MedicineKurumeJapan
  3. 3.Department of Pathophysiological Science, Faculty of Pharmaceutical SciencesHokuriku UniversityToyamaJapan
  4. 4.Department of Pathology, Graduate School of Biomedical SciencesHiroshima UniversityHiroshimaJapan

Personalised recommendations